What’s Next for UCB S A ORDINARY SHARES BELGIUM (OTCMKTS:UCBJF) After Having Less Shares Shorted?

March 14, 2018 - By Vivian Currie

The stock of UCB S A ORDINARY SHARES BELGIUM (OTCMKTS:UCBJF) registered a decrease of 66.62% in short interest. UCBJF’s total short interest was 24,000 shares in March as published by FINRA. Its down 66.62% from 71,900 shares, reported previously. With 2,200 shares average volume, it will take short sellers 11 days to cover their UCBJF’s short positions. The short interest to UCB S A ORDINARY SHARES BELGIUM’s float is 0.02%.

It closed at $82.7 lastly. It is down 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. The company has market cap of $15.44 billion. The Company’s core products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn??s disease, psoriatic arthritis, and rheumatoid arthritis; Keppra, Vimpat, and Briviact for epilepsy; and Neupro for Parkinson??s disease and restless legs syndrome. It has a 16.82 P/E ratio. The firm also offers Zyrtec and Xyzal for allergy; Venlafaxine ER for depressive and anxiety disorders; Nootropil for cognitive disorders; and Xyrem for narcolepsy.

Another recent and important UCB SA (OTCMKTS:UCBJF) news was published by Fiercebiotech.com which published an article titled: “UCB spins out neuro startup with €17M from Novo, Johnson & Johnson” on February 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: